financetom
Business
financetom
/
Business
/
Marathon Petroleum's Q3 Adjusted Income Increases, Total Revenue Declines
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Marathon Petroleum's Q3 Adjusted Income Increases, Total Revenue Declines
Nov 4, 2025 4:04 AM

06:53 AM EST, 11/04/2025 (MT Newswires) -- Marathon Petroleum ( MPC ) reported Q3 adjusted income Tuesday of $3.01 per diluted share, up from $1.87 a year earlier.

Analysts polled by FactSet expected $3.15.

Total revenue and other income for the quarter ended Sept. 30 were $35.85 billion, compared with $35.37 billion a year earlier.

Analysts polled by FactSet expected $33.45 billion.

Shares of Marathon Petroleum ( MPC ) were down more than 6% in recent premarket activity Tuesday.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Infomedia Announces Acquisition of Veact in Europe, Expanding Global Automotive Aftersales Ecosystem
Infomedia Announces Acquisition of Veact in Europe, Expanding Global Automotive Aftersales Ecosystem
Jun 9, 2026
SYDNEY and MUNICH, June 9, 2026 /PRNewswire/ -- Infomedia, a global leader in automotive aftersales technology, has completed the acquisition of Veact GmbH, a leading European provider of data activation, predictive service marketing, and aftersales customer management solutions in the automotive industry. Financial terms of the transaction were not disclosed. This acquisition underscores Infomedia's strategy to broaden its global footprint...
Moderna, University of Oxford Receive UK Approval to Begin Study of Cancer Vaccine
Moderna, University of Oxford Receive UK Approval to Begin Study of Cancer Vaccine
Jun 9, 2026
03:58 AM EDT, 06/09/2026 (MT Newswires) -- Moderna ( MRNA ) and the University of Oxford have received authorization from the UK Medicines and Healthcare products Regulatory Agency to begin a phase 1/2 study of mRNA-4194, an investigational cancer vaccine for people with lynch syndrome, according to a Monday statement. Lynch syndrome is an inherited condition that results in high...
Form 8.3
Form 8.3
Jun 9, 2026
LONDON--(BUSINESS WIRE)--   FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Computershare Trustees (Jersey) Limited as trustee of the Schroders Employee Benefit Trust (b) Owner or controller of interests and short positions disclosed,...
Zai Lab Says China Approves Tivdak for Cervical Cancer Treatment
Zai Lab Says China Approves Tivdak for Cervical Cancer Treatment
Jun 9, 2026
03:56 AM EDT, 06/09/2026 (MT Newswires) -- Zai Lab ( ZLAB ) received approval from China's National Medical Products Administration for Tivdak to treat adults with recurrent or metastatic cervical cancer whose disease progressed on or after chemotherapy, the company said Monday. The approval was supported by results from a phase 3 trial in which Tivdak showed a 45% reduction...
Copyright 2023-2026 - www.financetom.com All Rights Reserved